LEIDEN, Netherlands and SITTARD, Netherlands, Aug. 17, 2006 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Swiss Exchange:CRX) and technology partner DSM Biologics today announced the signing of a second PER.C6(R) license agreement with MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX). This license agreement allows MorphoSys to use the PER.C6(R) cell line in the production of clinical grade material for the development of its proprietary therapeutic antibody program MOR103. MOR103 is a fully human HuCAL(R) antibody, developed in the area of inflammatory diseases, such as rheumatoid arthritis.
